Table 3.
Phase I disease specific combination studies of bortezomib
| Patient population | Advanced NSCLC | Advanced ovarian tumors | Advanced head and neck cancer | Advanced colorectal cancer |
|---|---|---|---|---|
| Number of patients | 16 | 15 | 17 | 13 |
| Schedule | Starting dose of 1.0 mg/m2 iv on days 1, 4, 8, 11 + gemcitabine 800 mg/m2 on days 1, 8 + CBDCA AUC 5 on day 1 q3 weeks | Starting dose of 0.75 mg/m2 iv on days 1, 4, 8, 11 + CBDCA AUC 5 on day 1 q3 weeks | Starting dose of 0.7 mg/m2 iv on days 1, 4, 8, 11 + CDDP 30 mg/m2 on day 1 q3 weeks | Starting dose of 1.03 mg/m2 iv on days 1, 8, 15 + FOLFOX-4 q2 weeks |
| Best response obtained | 4 PR | 2 CR | NR | 5 PR |
| 5 SD | 5 Pr | 5 SD | ||
| Toxicity observed | Myelosuppression | Diarrhea | Thrombocytopenia | Myelosuppression and diarrhea |
Abbreviations: NSLC, nonsmall-cell lung cancer; PR, partial response; SD, stable disease; NR, not reported; CBDCA, carboplatin; CDDP, cisplatin.